Prof. Christian Ottensmeier will give a lecture entitled: 'Activating tumour reactive T cells for cancer immunotherapy? there may be a problem'.


Abstract of the lecture:Immunotherapy has revolutionised cancer treatment. The key drugs, anti-PD1 or anti-PDL1 antibodies release pre-existing T cells that recognise tumour antigens. Where such T cells are lacking in number anti-cancer vaccination may train new tumour reactive T cells. However while T cells in the tumour microenvironment can have an effector function, there are also significant populations of T cells that have a regulatory phenotype. Vaccination may thus activate effector and inhibitory T cells at the same time. Which antigens drive regulatory over effector T cells is currently unclear but this may profoundly affect the outcome of anti-tumour vaccination, particularly as checkpoint inhibitors are likely to amplify this effect.


Pathologists - all levels


Prof. Christian Ottensmeier MD PhD FRCP is a Professor of Immuno-Oncology at of University of Liverpool, the Liverpool Head and Neck Center and Director for Clinical Research at Clatterbridge Cancer Center

For more information, please contact: [email protected]

  • 16:00 - 18/10/2023 to 17:00 - 18/10/2023
  • Virtual event, United Kingdom